Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Int Urol Nephrol ; 54(3): 679-686, 2022 Mar.
Article in English | MEDLINE | ID: mdl-34251604

ABSTRACT

PURPOSE: Changes over time of phenotype and prognosis in CKD patients starting nephrology care are undefined. This information is critical to correctly plan and optimize healthcare resources and clinical management in tertiary care. METHODS: We performed a long-term observational cohort study including 2,866 non-dialysis CKD patients newly referred to our nephrology clinic from 2004 to 2018. Three cohorts were constituted based on 5-year calendar intervals (2004-2008, 2009-2013, and 2014-2018). The changes over time of main demographic, clinical and laboratory characteristics were compared among the three cohorts. We also compared between cohorts the risk of renal death (combined endpoint of renal replacement therapy-RRT, or death before RRT) as well as of the single components (RRT or death). RESULTS: Across the three cohorts, we detected a significant increase in the prevalence of age ≥ 75 years (from 22.0 to 28.4%), male gender (from 53.1 to 62.1%), diabetes (from 32.6 to 39.5%), severe proteinuria ≥ 500 mg/24 h (from 46.9 to 52.4%). Mean eGFR at referral declined from 56.8 ± 27.0 to 49.6 ± 26.1 mL/min/1.73m2. Incidence of renal death significantly declined over time (5.36, 3.22 and 4.54/100 pts-year in 2004-2008, 2009-2013 and 2014-2018 cohorts, respectively). As compared with patients referred in 2004-2008, adjusted risk of renal death was lower in patients referred in 2009-2013 (HR 0.49, 95%CI 0.34-0.69) and 2014-2018 (HR 0.61, 95%CI 0.45-0.84). Similar results were obtained for RRT, while mortality did not change over time. CONCLUSIONS: In the last 15 years, phenotype of newly referred CKD patients has remarkably changed with increasing frequency of older patients and more severe disease; however, renal survival improved suggesting greater efficacy of nephrology care.


Subject(s)
Renal Insufficiency, Chronic/therapy , Aged , Cohort Studies , Female , Humans , Male , Middle Aged , Phenotype , Prognosis , Referral and Consultation , Renal Dialysis , Renal Insufficiency, Chronic/genetics , Renal Insufficiency, Chronic/mortality , Survival Rate , Time Factors
2.
G Ital Nefrol ; 36(4)2019 Jul 24.
Article in Italian | MEDLINE | ID: mdl-31373467

ABSTRACT

Infections to the peritoneal catheter are common in Peritoneal Dialysis (PD). We report the clinical case of a 49-year-old male patient in PD, who showed an atypical manifestation of tunnel infection caused by Staphylococcus aureus. The infection was characterized by a little abscess, on the left pararectal abdominal line, 6 cm far from exit-site of the peritoneal catheter. The diagnosis was made using ultrasonography (US), which showed a fistulous communication from subcutaneous cuff to the skin. We treated the infection conservatively by performing cuff-shaving and drainage of the abscess, associated to antibiotic therapy (teicoplanin). Due to the persistence of the infection, we added oral and topical rifampicin, and advanced medication with freez-dried collagen plant impregnated with extended-release gentamicin. The complete resolution of the infection allowed us to avoid removing the catheter.


Subject(s)
Abdominal Wall , Abscess/microbiology , Catheter-Related Infections/microbiology , Peritoneal Dialysis/instrumentation , Polycystic Kidney, Autosomal Dominant/complications , Staphylococcal Infections/microbiology , Abscess/diagnostic imaging , Anti-Bacterial Agents/therapeutic use , Catheter-Related Infections/diagnostic imaging , Catheter-Related Infections/therapy , Combined Modality Therapy/methods , Drainage , Gentamicins/therapeutic use , Humans , Male , Middle Aged , Peritoneal Dialysis, Continuous Ambulatory , Polycystic Kidney, Autosomal Dominant/therapy , Rifampin/therapeutic use , Staphylococcal Infections/therapy , Staphylococcus aureus , Teicoplanin/therapeutic use , Ultrasonography
3.
G Ital Nefrol ; 36(3)2019 Jun 11.
Article in Italian | MEDLINE | ID: mdl-31250998

ABSTRACT

About 90%of patients with chronic kidney disease (CKD) have arterial hypertension; the main international guidelines recommend maintaining blood pressure (BP) values below 130/80 mmHg to reduce the cardio-renal risk in this population. Twenty-four-hour Ambulatory Blood Pressure Monitoring (ABPM) is the golden standard for the identification of the BP profiles and patterns, as well as for the assessment of the circadian rhythm and BP variability. The correct interpretation of ABPM allows to optimize anti-hypertensive treatment and to reduce cardio-renal risk in CKD patient. In fact, in patients with CKD, the ABPM has a greater role in terms of renal and cardio-vascular prognosis when compared to clinical BP measurements. Patients with ABPM in target present a low cardio-renal risk, regardless of clinical BP values; on the contrary, if the clinical PA is normal and the ABPM not in target, this risk increases significantly. Moreover, in the CKD population, non-dipping is associated with a higher risk of cardiovascular events and end stage renal disease (ESRD), making identifying nocturnal hypertension greatly important. Therefore, ABPM is an instrument of primary importance in the diagnostic and therapeutic work-out of renal patients.


Subject(s)
Blood Pressure Monitoring, Ambulatory , Hypertension/complications , Hypertension/diagnosis , Renal Insufficiency, Chronic/complications , Humans
4.
G Ital Nefrol ; 36(2)2019 Apr.
Article in Italian | MEDLINE | ID: mdl-30983178

ABSTRACT

Renal and hepatic cysts infections are among the most important infectious complications of ADPKD and often require hospitalization. Liver cysts are even more complex than renal cysts and their diagnosis and treatment are quite controversial. We report the case of a 58-year-old patient with ADPKD undergoing peritoneal dialysis treatment. He presented fever and severe asthenia and was diagnosed with a hepatic cyst infection. Given the presence of the peritoneal catheter, and in order to facilitate the targeted treatment of the infection, we administered antibiotics (ceftazidime and teicoplanin) in the bags used for peritoneal dialysis exchanges for 4 weeks, obtaining the complete disappearance of symptoms and laboratory and ultrasound alterations. Intraperitoneal antibiotics administration in the treatment of infected hepatic cysts represents an effective and safe therapeutic alternative, never described in literature so far.


Subject(s)
Bacterial Infections/complications , Cysts/etiology , Liver Diseases/etiology , Polycystic Kidney, Autosomal Dominant/complications , Renal Dialysis , Anti-Bacterial Agents/administration & dosage , Bacterial Infections/diagnostic imaging , Bacterial Infections/drug therapy , Ceftazidime/administration & dosage , Cysts/diagnostic imaging , Cysts/drug therapy , Humans , Infusions, Parenteral , Liver Diseases/diagnostic imaging , Liver Diseases/drug therapy , Male , Middle Aged , Renal Insufficiency, Chronic/therapy , Teicoplanin/administration & dosage
5.
Nutrients ; 10(6)2018 06 06.
Article in English | MEDLINE | ID: mdl-29882800

ABSTRACT

BACKGROUND: A clear evidence on the benefits of reducing salt in people with chronic kidney disease (CKD) is still lacking. Salt restriction in CKD may allow better control of blood pressure (BP) as shown in a previous systematic review while the effect on proteinuria reduction remains poorly investigated. METHODS: We performed a meta-analysis of randomized controlled trials (RCTs) evaluating the effects of low versus high salt intake in adult patients with non-dialysis CKD on change in BP, proteinuria and albuminuria. RESULTS: Eleven RCTs were selected and included information about 738 CKD patients (Stage 1⁻4); urinary sodium excretion was 104 mEq/day (95%CI, 76⁻131) and 179 mEq/day (95%CI, 165⁻193) in low- and high-sodium intake subgroups, respectively, with a mean difference of −80 mEq/day (95%CI from −107 to −53; p <0.001). Overall, mean differences in clinic and ambulatory systolic BP were −4.9 mmHg (95%CI from −6.8 to −3.1, p <0.001) and −5.9 mmHg (95%CI from −9.5 to −2.3, p <0.001), respectively, while clinic and ambulatory diastolic BP were −2.3 mmHg (95%CI from −3.5 to −1.2, p <0.001) and −3.0 mmHg (95%CI from −4.3 to −1.7; p <0.001), respectively. Mean differences in proteinuria and albuminuria were −0.39 g/day (95%CI from −0.55 to −0.22, p <0.001) and −0.05 g/day (95%CI from −0.09 to −0.01, p = 0.013). CONCLUSION: Moderate salt restriction significantly reduces BP and proteinuria/albuminuria in patients with CKD (Stage 1⁻4).


Subject(s)
Diet, Sodium-Restricted , Kidney/physiopathology , Renal Insufficiency, Chronic/diet therapy , Sodium Chloride, Dietary/adverse effects , Adult , Aged , Albuminuria/diet therapy , Albuminuria/physiopathology , Blood Pressure , Evidence-Based Medicine , Female , Humans , Male , Middle Aged , Randomized Controlled Trials as Topic , Renal Insufficiency, Chronic/diagnosis , Renal Insufficiency, Chronic/physiopathology , Treatment Outcome
6.
G Ital Nefrol ; 35(1)2018 Feb.
Article in Italian | MEDLINE | ID: mdl-29390240

ABSTRACT

Hyperuricemia is defined as serum uric acid values greater than 6 mg/dl and could occur either due to hyperproduction or as a result of reduced renal excretion, which exceeds gut compensation. In Italy, prevalence is around 12% of the general population and increases in renal disease up to 60%. Recent experimental studies demonstrated a role of uric acid in the development of arterial hypertension and systemic arteriosclerosis, with an increase in cardiovascular risk. It also appears from observational studies that high uric acid is an independent risk factor associated with de novo onset of chronic kidney disease after adjustment of main confounding variables. Hyperuricemic subjects treated with febuxostat, a selective inhibitor of xantino-oxidase, showed in RCTs a better control of hyperuricaemia in comparison with those receiving allopurinol. Moreover, observational studies indicate that urate lowering treatment could be helpful in reducing cardiovascular events as well as in slowing the progression of chronic kidney disease; randomized controlled studies, designed to assess as primary outcome the nephroprotective effect of urate lowering treatment, are in progress.


Subject(s)
Hyperuricemia/complications , Renal Insufficiency, Chronic/etiology , Allopurinol/therapeutic use , Arteriosclerosis/etiology , Disease Progression , Febuxostat/therapeutic use , Humans , Hypertension/etiology , Hyperuricemia/drug therapy , Hyperuricemia/epidemiology , Hyperuricemia/physiopathology , Observational Studies as Topic , Randomized Controlled Trials as Topic , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...